Mondelez International, Inc. (MDLZ)

Stalwart

FairStock Score: 36/100 — MIXED

Key Financials

Current Price$60.44
Market Cap$75.1B
P/E Ratio29.92
ROE10.16%
Dividend Yield3.22%
SectorConsumer Defensive

Strengths

Concerns

AI Analysis

Mondelez presents a classic case of a quality business trading at an unreasonable price. The company commands genuine competitive moats through its iconic brand portfolio—Oreo, Ritz, and Cadbury are household names with pricing power across 150+ countries. The diversified geographic footprint and exposure to emerging markets provide structural growth tailwinds. However, I must be candid: at $58.17, this stock fails our margin of safety test dramatically. The Graham Number of $15.36 versus the current price represents a 278% negative margin—we're paying nearly four times intrinsic value. The valuation metrics confirm my concerns: a P/E of 29.74 is steep for a mature snack company, and an EV/EBITDA of 66.48 is frankly absurd. The ROCE of 3.24% and ROE of 9.33% are mediocre—capital isn't being deployed efficiently despite the market's enthusiasm. While free cash flow of $3.6B demonstrates operational strength and supports the modest 2.7% FCF yield, the Altman Z-Score of 1.74 suggests moderate financial stress. The leverage at 0.85 D/E is manageable but worth monitoring. This is a business I'd happily own at $20, but at $58, I'm forced to pass. Quality at the wrong price destroys wealth as surely as mediocrity at any price.

Bull Case

Mondelez's portfolio of iconic brands and global distribution network position it to benefit from secular snacking trends and emerging market growth. Strong FCF generation of $3.6B provides resilience and supports shareholder returns, while the company's defensive characteristics (low beta) offer portfolio stability during market downturns.

Bear Case

The astronomical valuation disconnected from fundamentals represents significant downside risk. With ROCE barely above the cost of capital and modest growth prospects in a mature category, mean reversion toward fair value could deliver 60%+ losses to patient shareholders.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer